Cambridge, UK and Cambridge, MA 5/15/14; Cambridge, MA 5/15/14—Gene-editing technology firm Horizon Discovery has acquired the CombinatoRX services business and related assets from biopharmaceutical company Zalicus for £4.74 million ($8 million = £0.59 = $1). The business consists of the cHTS (combination high-throughput screening) platform and Chalice software for the screening and analysis of thousands of complementary drug combinations for the identification of personalized-medicine solutions for cancer treatment. CHTS and Chalice revenue grew 10% in 2013 to $8.1 million. Additional assets include a library of approximately 800 cell lines, and an extensive compound and chemical-probe library. Horizon will create Horizon CombinatoRx, based in Cambridge, Massachusetts, to provide services to research organizations. “The deployment of the scalable and proven cHTS and Chalice Informatics platform with our world-leading translational genomics platform significantly broadens the portfolio of discovery-research services we can offer to our global customer base,” stated Horizon CEO Dr. Darrin M. Disley. “The cHTS platform enables the deep exploration of efficacy and mechanistic synergies of thousands of drug combinations with the potential to treat serious diseases like cancer by simultaneously modulating multiple biological pathways with targeted therapeutic regimens.” Horizon also stated that the acquisition provides it with a base to grow its business operations in North America. Jeb Ledell, vice president of Corporate Operations at Zalicus, will become COO of the new subsidiary. The transaction is expected to close in June.